Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 12/20 | 0.98 |
| ▸ | ROCK1 known ✓ | Q13464 | 11/20 | 0.98 |
| ▸ | PRKD3 known ✓ | O94806 | 5/20 | 0.61 |
| ▸ | PRKCG known ✓ | P05129 | 5/20 | 0.61 |
| ▸ | PRKCB known ✓ | P05771 | 5/20 | 0.61 |
| ▸ | PRKCA known ✓ | P17252 | 5/20 | 0.61 |
| ▸ | PRKCH known ✓ | P24723 | 5/20 | 0.61 |
| ▸ | PRKCI known ✓ | P41743 | 5/20 | 0.61 |
| ▸ | PRKCE known ✓ | Q02156 | 5/20 | 0.61 |
| ▸ | PRKCQ known ✓ | Q04759 | 5/20 | 0.61 |
| ▸ | PRKCZ known ✓ | Q05513 | 5/20 | 0.61 |
| ▸ | PRKCD known ✓ | Q05655 | 5/20 | 0.61 |
| ▸ | PRKD1 known ✓ | Q15139 | 5/20 | 0.61 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.56 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.56 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.56 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.56 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.56 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.56 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20644189 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL17946426 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL190414 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL19543804 | 0.90 | ROCK2 (0.83) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL13716157 | 0.86 | ROCK2 (1.00) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL13716079 | 0.86 | ROCK2 (0.77) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL19543799 | 0.86 | ROCK2 (0.77) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL13715989 | 0.84 | ROCK2 (0.78) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL13716058 | 0.84 | ROCK2 (0.78) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL4729640 | 0.83 | ROCK2 (0.74) | ROCK2ROCK1PRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709477-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | The Texas A&M University System (US) | 2026-03-18 | — | — | EP | claimed |
| WO-2024238454-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2024-11-21 | — | — | WO | claimed |
| EP-4709477-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | The Texas A&M University System (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3985126-B1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2026-03-04 | — | — | EP | disclosed |
| EP-4355915-B1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | GENFIT (FR) | 2026-02-04 | — | — | EP | disclosed |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-03 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-3684954-B1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC FATTY LIVER DISEASES, NON-ALCOHOLIC STEATOHEPATITIS AND/OR LIVER FIBROSIS | GENFIT (FR) | 2025-11-26 | — | — | EP | disclosed |
| EP-3612176-B1 | COMBINATION COMPRISING THE PPAR AGONIST ELAFIBRANOR AND AN ACETYL-COA CARBOXYLASE (ACC) INHIBITOR SELECTED FROM CP-640186, GEMCABENE, GS-0976 TO TREAT INFLAMMATORY, METABOLIC, FIBROTIC OR CHOLESTATIC DISEASES | GENFIT (FR) | 2025-09-17 | — | — | EP | disclosed |
| US-20250281480-A1 | PHARMACEUTICAL DRY POWDER INHALATION FORMULATION | BAYER AG (DE) | 2025-09-11 | — | — | US | disclosed |
| EP-3985126-A1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | Genfit (FR) | 2022-04-20 | — | — | EP | disclosed |
| EP-3980070-A1 | METHOD FOR TREATMENT OF AT RISK PATIENTS | Genfit (FR) | 2022-04-13 | — | — | EP | disclosed |
| US-20220089591-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2022-03-24 | — | — | US | disclosed |
| US-20220089567-A1 | RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF | BioAxone BioSciences, Inc. (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220089567-A1 | RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF | BioAxone BioSciences, Inc. (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220088010-A1 | Co-Administration of inhibitors to produce insulin producing gut cells | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-03-24 | — | — | US | disclosed |
| US-20220089567-A1 | RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF | BioAxone BioSciences, Inc. (US) | 2022-03-24 | — | — | US | disclosed |
| EP-3966226-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |
| CN-114010788-A | Channel modulators | 奥克兰联合服务有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | ROCK2 2728/4885ROCK1 2161/4885PRKD3 2897/4885 |
| US-20220089567-A1 | RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF | RHOA, ARHGDIA, ROCK1 | ROCK2 4/4885ROCK1 3/4885PRKD3 423/4885 |
| US-20220089591-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | AADAC, GLS, NAT1 | ROCK2 4726/4885ROCK1 4660/4885PRKD3 1780/4885 |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | ADRA2C, ADRB3, ADRB2 | ROCK2 3019/4885ROCK1 3907/4885PRKD3 1698/4885 |
| US-20250281480-A1 | PHARMACEUTICAL DRY POWDER INHALATION FORMULATION | H1-5, PAH, HRH2 | ROCK2 625/4885ROCK1 1555/4885PRKD3 3662/4885 |
| US-20220088010-A1 | Co-Administration of inhibitors to produce insulin producing gut cells | IAPP, GPR119, FOXO1 | ROCK2 18/4885ROCK1 15/4885PRKD3 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.